Asthma Breath Biomarker Assessment — ABBA  

Asthma Acute Clinical Trial

Official title: Exhaled Breath Biomarkers in Acute Asthma: A Feasibility Study

Status Completed

Clinical Trial Summary

This study aims to assess the feasibility of capturing data on exhaled breath compounds during an acute asthma exacerbation. In addition to assessing the feasibility of such a study the investigators will collect data on exploratory outcomes including the ability of breath biomarkers to distinguish between controlled and exacerbated states and their ability to differentiate between triggers of exacerbation.

Clinical Trial Description

This will be a longitudinal observational study in which the investigators assess the ability to capture information on volatile organic compounds in exhaled breath during an acute asthma exacerbation using two different approaches:

A) Recruitment and assessment of patients in secondary care during an acute exacerbation of their asthma; patients to be re-assessed once their asthma is stable and controlled.

B) Recruitment of clinically stable outpatients who are at increased risk of exacerbation by virtue of having had an acute exacerbation within the previous 12 months. Participants to be followed for a period of up to 12 months; assessed in the event of an exacerbation; and re-assessed once controlled. ;

Related Conditions & MeSH terms

• Asthma
• Asthma Acute

• NCT number: NCT03084016
• Study type: Observational
• Source: University of East Anglia
• Status: Completed
• Start date: March 6, 2017
• Completion date: December 31, 2018